Antagonists of IL-6 to prevent or treat thrombosis
AssigneeAlderbio Holdings LLC
InventorJeffrey T. L. Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
Claims19
A method of treating a patient having a disease or condition associated with hypercoagulation, comprising administering to the patient an IL-6 antibody or antibody fragment, whereby the patient's coagulation profile is improved or restored to normal, wherein the anti-IL-6 antibody or antibody fragment comprises a variable light (VL) polypeptide comprising the VL complementarity-determining regions (CDRs) of SEQ ID NO:
- 87, SEQ ID NO:
- 88, and SEQ ID NO:
- 89;
- which correspond to the VL CDRs of the VL chain sequence of SEQ ID NO:
- 85, and further comprises a variable heavy (VH) polypeptide comprising the CDRs of sequences of SEQ ID NO:
- 90, SEQ ID NO:
- 91, and SEQ ID NO:
- 92;
- which correspond to the VH CDRs of the variable heavy chain sequence of SEQ ID NO:
- 86.
Dependencies are inferred from the claim text.